Nitrogen permease regulator‑like 2 enhances sensitivity to oxaliplatin in colon cancer cells

Liu,Ming‑Na; Liu,Ai‑Yun; Du,Ya‑Ju; Pei,Feng‑Hua; Wang,Xin‑Hong; Chen,Jing; Liu,Dan; Liu,Bing‑Rong

doi:10.3892/mmr.2015.3495

Nitrogen permease regulator‑like 2 enhances sensitivity to oxaliplatin in colon cancer cells

Authors:
- Ming‑Na Liu
- Ai‑Yun Liu
- Ya‑Ju Du
- Feng‑Hua Pei
- Xin‑Hong Wang
- Jing Chen
- Dan Liu
- Bing‑Rong Liu
View Affiliations

Affiliations: Department of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150080, P.R. China
Published online on: March 13, 2015 https://doi.org/10.3892/mmr.2015.3495
Pages: 1189-1196

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide. Chemotherapeutic compounds used for the treatment of CRC include oxaliplatin (L‑OHP). While L‑OHP improves CRC survival, certain patients are resistant. The nitrogen permease regulator like‑2 (NPRL2) gene is a candidate tumor suppressor gene that resides in a 120‑kb homozygous deletion region on chromosome 3p21.3. In the present study, it was demonstrated that NPRL2 overexpression increases the sensitivity of HCT116 cells to L‑OHP. The IC50 of L‑OHP was decreased in cells transduced with NPRL2 compared with negative control (NC) cells and the effect of NPRL2 on L‑OHP sensitivity was time dependent. Following NPRL2 transduction in HCT116 cells, the cell cycle was arrested in the G1 phase and a partial decrease in the S phase population was observed. Flow cytometric analysis revealed that NPRL2 transduction and L‑OHP treatment increased apoptosis compared with NC cells. The mechanism through which NPRL2 overexpression enhances L‑OHP sensitivity involves downregulation of the functions of the phosphatidylinositol 3‑kinase/Akt/mammalian target of rapamycin network. Furthermore, L‑OHP upregulated caspase‑3 and caspase‑9 to promote apoptosis in NPRL2‑overexpressing cells compared with cells that were transduced with NPRL2 or treated with L‑OHP and NC cells (P<0.01). NPRL2 overexpression led to the downregulation of CD24, which could significantly reduce tumor invasiveness and decrease the metastatic capacity of HCT116 cells. These mechanisms are likely active in other types of cancer and may be exploited for the development of novel cancer therapies.

View Figures

View References

1	Perazzo F, Piaggio F, Krupitzki H, et al: Clinical-pathological features and gene profile in colorectal cancer. Medicina (B Aires). 73:417–422. 2013.In Spanish.
2	Ahmed FE: Gene-gene, gene-environment & multiple interactions in colorectal cancer. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 24:1–101. 2006. View Article : Google Scholar : PubMed/NCBI
3	Patel BB and Majumdar AP: Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr Cancer. 61:842–846. 2009. View Article : Google Scholar
4	Lerman MI and Minna JD: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res. 60:6116–6133. 2000.PubMed/NCBI
5	Wistuba II, Behrens C, Virmani AK, Mele G, et al: High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 60:1949–1960. 2000.PubMed/NCBI
6	Li J, Wang F, Haraldson K, Protopopov A, et al: Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res. 64:6438–6443. 2004. View Article : Google Scholar : PubMed/NCBI
7	Schenk PW, Brok M, Boersma AW, et al: Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill. Mol Pharmacol. 64:259–268. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ueda K, Kawashima H, Ohtani S, et al: The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 66:9682–9690. 2006. View Article : Google Scholar : PubMed/NCBI
9	Chan AT and Giovannucci EL: Primary prevention of colorectal cancer. Gastroenterology. 138:2029–2043. 2010. View Article : Google Scholar : PubMed/NCBI
10	Poynter JN, Haile RW, Siegmund KD, et al: Colon Cancer Family Registry: Associations between smoking, alcohol consumption and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev. 18:2745–2750. 2009. View Article : Google Scholar : PubMed/NCBI
11	Bostick RM, Potter JD, Kushi LH, Sellers TA, Steinmetz KA, McKenzie DR, Gapstur SM and Folsom AR: Sugar, meat and fat intake and non-dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes Control. 5:38–52. 1994. View Article : Google Scholar : PubMed/NCBI
12	Yang AD, Fan F, Camp ER, van Buren G, Liu W, et al: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153. 2006. View Article : Google Scholar : PubMed/NCBI
13	Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, et al: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
14	De Larco JE, Wuertz BR, Manivel JC and Furcht LT: Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res. 61:2857–2861. 2001.PubMed/NCBI
15	Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, et al: Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 31:277–283. 2007.PubMed/NCBI
16	Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, et al: Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer. 10:2192010. View Article : Google Scholar : PubMed/NCBI
17	Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, et al: Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 68:516–520. 2008. View Article : Google Scholar : PubMed/NCBI
18	Zabarovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 21:6915–6935. 2002. View Article : Google Scholar : PubMed/NCBI
19	Ji L, Nishizaki M, Gao B, et al: Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res. 62:2715–2720. 2002.PubMed/NCBI
20	Zhou BB and Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature. 408:433–439. 2000. View Article : Google Scholar : PubMed/NCBI
21	Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, et al: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 210:767–776. 2010. View Article : Google Scholar : PubMed/NCBI
22	Maira SM, Voliva C and Garcia-Echeverria C: Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets. 12:223–238. 2008. View Article : Google Scholar : PubMed/NCBI
23	Ekstrand AI, Jonsson M, Lindblom A, Borg A and Nilbert M: Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer. 9:125–129. 2010. View Article : Google Scholar
24	Awasthi N, Yen PL, Schwarz MA and Schwarz RE: The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. J Cell Biochem. 113:784–791. 2012. View Article : Google Scholar
25	Glienke W, Maute L, Wicht J and Bergmann L: The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tumour Biol. 33:757–765. 2012. View Article : Google Scholar
26	Armegnol G, Rojo F, Castellví J, et al: 4E-binding protein 1: a key molecular ‘funnel factor’ in human cancer with clinical implications. Cancer Res. 67:7551–7555. 2007. View Article : Google Scholar
27	Xu G, Zhang W, Bertram P, et al: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol. 24:893–900. 2004.PubMed/NCBI
28	Lim SC and Oh SH: The role of CD24 in various human epithelial neoplasias. Pathol Res Pract. 201:479–486. 2005. View Article : Google Scholar : PubMed/NCBI
29	Sammar M, Aigner S, Hubbe M, Schirrmacher V, Schachner M, Vestweber D and Altevogt P: Heat-stable antigen (CD24) as ligand for mouse P-selectin. Int Immunol. 6:1027–1036. 1994. View Article : Google Scholar : PubMed/NCBI
30	Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P and Ley K: CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J. 12:1241–1251. 1998.PubMed/NCBI
31	Yong CS, Ou Yang CM, Chou YH, Liao CS, Lee CW and Lee CC: CD44/CD24 expression in recurrent gastric cancer: A retrospective analysis. BMC Gastroenterol. 12:952012. View Article : Google Scholar : PubMed/NCBI
32	Takahashi M, Nakajima M, Ogata H, Domeki Y, Ohtsuka K, Ihara K, Kurayama E, Yamaguchi S, Sasaki K, Miyachi K and Kato H: CD24 expression is associated with progression of gastric cancer. Hepatogastroenterology. 60:653–658. 2013.